Ascendis Pharma A/s

Ascendis Pharma Ophthalmology Division A/s

Ascendis Pharma Oncology Division A/s

Tobias Voigt

Harald Rau

Nicola Bisek

Burkhardt Laufer

Ulrich Hersel

Juha Punnonen

Thomas Knappe

Sebastian Stark

Kennett Sprogøe

Dirk Vetter

Guillaume Maitro

Joachim Zettler

Mathias Krusch

Torben Lessmann

Samuel Weisbrod

Romy Reimann

David B Rosen

Nora Kaluza

Franziska Hahn

Yang Yang-malten

Lars Holten-andersen

Kennett SprogØe

Luis Zuniga

The present invention relates to hydrogel prodrug compositions comprising cross-linked hyaluronic acid (HA), or a derivative or a salt thereof, wherein the cross-linker system comprises a biodegradable spacer, wherein the cross-linked HA comprises a conjugated drug-linker, and wherein the linker is capable of releasing the drug under physiological conditions. The present invention further relates to methods for preparing the hydrogel prodrug compositions. The present invention further relates to methods for treating an ocular condition using the hydrogel compositions.

Hydrogel cross-linked hyaluronic acid prodrug compositions and methods

The present invention relates to biodegradable polyethylene glycol based water-insoluble hydrogels comprising backbone moieties which are interconnected by hydrolytically degradable bonds, the backbone moieties further comprising reactive functional groups, wherein the water-insoluble hydrogel is further characterized in that the ratio between the time period for the complete degradation of the hydrogel by hydrolysis of the degradable bonds into water-soluble degradation products comprising one or more backbone moieties and the time period for the release of the first 10 mol-% of water-soluble degradation products comprising one or more backbone moieties based on the total amount of backbone moieties in the hydrogel is greater than 1 and equal to or less than 2. The invention further relates to conjugates of such hydrogels with ligands or ligating groups, prodrugs and pharmaceutical compositions as well as their use in a medicament.

Biodegradable polyethylene glycol based water-insoluble hydrogels

The present invention relates to a pharmaceutical composition comprising one or more pharmaceutically acceptable excipient(s) and a VEGF neutralizing prodrug, which comprises a VEGF neutralizing biologically active moiety, for use in a method for the treatment of one or more ocular conditions.

VEGF neutralizing prodrugs for the treatment of ocular conditions

The present invention relates to a process for the preparation of a hydrogel and to a hydrogel obtainable by said process. The present invention further relates to a process for the preparation of a hydrogel-spacer conjugate, to a hydrogel-spacer conjugate obtainable by said process, to a process for the preparation of a carrier-linked prodrug and to carrier-linked prodrugs obtainable by said process, in particular to carrier-linked prodrugs that provide for a controlled or sustained release of a drug from a carrier. In addition, the invention relates to the use of the hydrogel for the preparation of a carrier-linked prodrug.

Hydrogel prodrugs

The present invention relates to a terminal sterilization process for biodegradable PEG-based insoluble hydrogels using irradiation. The presence of a protective solvent ensures that the hydrogel remains intact with functionally preserved three-dimensional and physicochemical properties.

Sterilization of biodegradable hydrogels

Growing community of inventors

Heidelberg, Germany

Tobias Voigt